price month
addit thought ir
bottom line chanc speak bristol-my investor
relat briefli morn follow news compani receiv
second request ftc regard propos celgen acquisit
note second request sort common one
broad-bas request instead focus asset treatment
psoriasi assum mean celg market drug otezla
bmi inhibitor current phase develop
compani also phase asset early-stag trial psoriasi
expert ftc process given divers rang
asset across biopharma either alreadi market
develop treat psoriasi would surpris overlap
celg portfolio much ftc get comfort
convers bristol ir state see issu
ftc resolv also note regulatori
process relat deal proceed plan region
well also confirm met iss glass lewi
expect proxi advisori firm provid recommend
deal late week earli next week continu expect
deal close plan
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
compani mention price
